CluePoints, a leading provider of risk-based monitoring (RBM) and data quality oversight solutions for clinical trials, has announced that it will be expanding its operations in the US with the opening of a new office in Wayne (PA, USA).
The expansion marks a key milestone in CluePoints’ ambitious growth strategy that will see the company build its infrastructure to support its rapidly growing US client base.
CluePoints, which already provides its solutions to seven of the top ten global biopharmaceutical companies and notable CROs and medical device companies, has seen demand for its services increase, fueled by growing industry and regulatory recognition of the benefits of a centralized statistical monitoring (CSM) approach.
As a result, CluePoints has already grown its US commercial team with the appointment of two new business development executives; and, during the next 12 months, the company will increase its staff by 50%.
CluePoints’ US operations are being led by Steve Young, Chief Operations Officer, who will be supported by project managers and data analysts at the new office.
Their focus will be on developing and supporting both existing and new customers in the region, from small and mid-size organisations to large pharmaceutical companies and CROs.
“A strong presence in the US is a critical next step in our strategy, following momentous growth in demand for our solutions. Not only are our customers experiencing significant tangible cost benefits but industry regulations, especially the imminent revised ICH E6 (R2) GCP guidance, now insist that sponsors have a central statistical approach to driving data quality, integrity and oversight,” comments Steve Young.
“We chose Wayne for our operations because it is located within a key region for biotech, CRO, pharma and technology companies, and provides access to a rich talent pool to support our continuing growth.”